D2C7-IT and Atezolizumab Recurrent MG - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if the study drugs (D2C7-IT) and Atezolizumab can be safely and effectively given to people with malignant gliomas that have progressed or recurred.

What is the Condition Being Studied?

Grade III or IV malignant glioma (brain tumor) that has progressed or recurred

Who Can Participate in the Study?

-Adults 18+ who:
--Have been diagnosed with Grade III or IV malignant glioma that has progressed or recurred
--Are not currently taking a high dose of the steroid medicine called Decadron or dexamethasone
--Are not currently being treated with types of medicines that affect your immune system

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Have the study drug (D2C7-IT) put into the area of the tumor that is in your brain
-Stay in the hospital 3-4 days

2 weeks after your hospital stay you will be asked to come to the Duke clinic every 3 weeks (for up to 2 years) where you will have:
-An infusion (into the vein) of Atezolizumab (an immunotherapy)
-A physical exam
-A blood draw
-MRIs at certain visits or as needed

Study Details

Full Title
A Phase 1 Trial of D2C7-IT in Combination with Atezolizumab in Recurrent WHO Grade IV Malignant Glioma
Principal Investigator
Neuro-oncologist
Protocol Number
IRB: PRO00101898
NCT: NCT04160494
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698